Acridine carboxamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Acridine carboxamide (N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide) is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]

References[edit]

  1. ^ Dittrich C, Dieras V, Kerbrat P et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID 14578683. 
  2. ^ Caponigro F, Dittrich C, Sorensen JB et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID 11750842. 
  3. ^ Twelves C, Campone M, Coudert B et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. doi:10.1093/annonc/mdf121. PMID 12075748. 
  4. ^ Dittrich C, Coudert B, Paz-Ares L et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID 12565985.